Empagliflozin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Linagliptin and Metformin: A 24-Week Randomized, Double-Blind, Parallel-Group Trial

2016128 citationsJournal Article

Authors

Eirik Søfteland · Haukeland University Hospital

Juris J. Meier · Ruhr University Bochum

Bente Vangen · Boehringer Ingelheim (Norway)

Robert Toorawa

Mario Maldonado‐Lutomirsky · Boehringer Ingelheim (Germany)

Uli C. Broedl · Boehringer Ingelheim (Germany)

Abstract

Empagliflozin treatment for 24 weeks improved glycemic control and weight versus placebo as an add-on to linagliptin 5 mg and metformin and was well tolerated.

Topics & Keywords

Diabetes Treatment and Management Pancreatic function and diabetes Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 40, Issue 2, pp. 201-209

DOI: 10.2337/dc16-1347

Field-Weighted Citation Impact: 10.90